Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia

Masahiro Kajiguchi, Takahisa Kondo, Hideo Izawa, Masayoshi Kobayashi, Koji Yamamoto, Satoshi Shintani, Yasushi Numaguchi, Tomoki Naoe, Junki Takamatsu, Kimihiro Komori, Toyoaki Murohara

研究成果: Article

136 引用 (Scopus)

抄録

Background: Therapeutic angiogenesis using cell transplantation (TACT) is a treatment strategy for no-option patients with critical limb ischemia (CLI). However, because one-third of treated patients fail to respond, the present study was an exploration of the characteristics of responders and non-responders to this treatment regimen. Methods and Results: Seven CLI patients (3 with Buerger's disease, 4 with arteriosclerosis obliterans undergoing chronic hemodialysis (ASO-HD)) were treated according to the TACT protocol (n=6: bone marrow-mononuclear cells (MNCs); n=1: peripheral blood-MNCs). Subjective symptoms (visual analog scale) and objective findings (extent of ulcer, ankle-brachial pressure index, transcutaneous oxygen pressure, thermography and angiography) were assessed. Numbers of transplanted CD34+, CD133 + and CD34+CD133+ cells were counted. Changes in circulating CD34+ and CD133+ cell numbers were also examined before and after the treatment. All responders (n=3) had Buerger's disease, and ASO-HD patients did not respond well. Among the responders, the numbers of circulating CD34+ and CD133+ cells persistently increased for 1 month after the treatment, but not in non-responders. Conclusions: The TACT regimen improved CLI in patients with Buerger's disease but not in those with ASOHD in this small study. In responders, post procedural circulating CD34+ and CD133+ cells persistently increased for 1 month (ClinicalTrials.gov Identifier: NCT00145262, TACT-NAGOYA).

元の言語English
ページ(範囲)196-201
ページ数6
ジャーナルCirculation Journal
71
発行部数2
DOI
出版物ステータスPublished - 05-02-2007

Fingerprint

Cell Transplantation
Stem Cells
Ischemia
Extremities
Safety
Thromboangiitis Obliterans
Arteriosclerosis Obliterans
Therapeutics
Renal Dialysis
Pressure
Ankle Brachial Index
Visual Analog Scale
Bone Marrow Cells
Ulcer
Blood Cells
Angiography
Cell Count
Oxygen

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

これを引用

Kajiguchi, Masahiro ; Kondo, Takahisa ; Izawa, Hideo ; Kobayashi, Masayoshi ; Yamamoto, Koji ; Shintani, Satoshi ; Numaguchi, Yasushi ; Naoe, Tomoki ; Takamatsu, Junki ; Komori, Kimihiro ; Murohara, Toyoaki. / Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia. :: Circulation Journal. 2007 ; 巻 71, 番号 2. pp. 196-201.
@article{4cd9497b2c154cf89d310eb1dd204964,
title = "Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia",
abstract = "Background: Therapeutic angiogenesis using cell transplantation (TACT) is a treatment strategy for no-option patients with critical limb ischemia (CLI). However, because one-third of treated patients fail to respond, the present study was an exploration of the characteristics of responders and non-responders to this treatment regimen. Methods and Results: Seven CLI patients (3 with Buerger's disease, 4 with arteriosclerosis obliterans undergoing chronic hemodialysis (ASO-HD)) were treated according to the TACT protocol (n=6: bone marrow-mononuclear cells (MNCs); n=1: peripheral blood-MNCs). Subjective symptoms (visual analog scale) and objective findings (extent of ulcer, ankle-brachial pressure index, transcutaneous oxygen pressure, thermography and angiography) were assessed. Numbers of transplanted CD34+, CD133 + and CD34+CD133+ cells were counted. Changes in circulating CD34+ and CD133+ cell numbers were also examined before and after the treatment. All responders (n=3) had Buerger's disease, and ASO-HD patients did not respond well. Among the responders, the numbers of circulating CD34+ and CD133+ cells persistently increased for 1 month after the treatment, but not in non-responders. Conclusions: The TACT regimen improved CLI in patients with Buerger's disease but not in those with ASOHD in this small study. In responders, post procedural circulating CD34+ and CD133+ cells persistently increased for 1 month (ClinicalTrials.gov Identifier: NCT00145262, TACT-NAGOYA).",
author = "Masahiro Kajiguchi and Takahisa Kondo and Hideo Izawa and Masayoshi Kobayashi and Koji Yamamoto and Satoshi Shintani and Yasushi Numaguchi and Tomoki Naoe and Junki Takamatsu and Kimihiro Komori and Toyoaki Murohara",
year = "2007",
month = "2",
day = "5",
doi = "10.1253/circj.71.196",
language = "English",
volume = "71",
pages = "196--201",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "2",

}

Kajiguchi, M, Kondo, T, Izawa, H, Kobayashi, M, Yamamoto, K, Shintani, S, Numaguchi, Y, Naoe, T, Takamatsu, J, Komori, K & Murohara, T 2007, 'Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia', Circulation Journal, 巻. 71, 番号 2, pp. 196-201. https://doi.org/10.1253/circj.71.196

Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia. / Kajiguchi, Masahiro; Kondo, Takahisa; Izawa, Hideo; Kobayashi, Masayoshi; Yamamoto, Koji; Shintani, Satoshi; Numaguchi, Yasushi; Naoe, Tomoki; Takamatsu, Junki; Komori, Kimihiro; Murohara, Toyoaki.

:: Circulation Journal, 巻 71, 番号 2, 05.02.2007, p. 196-201.

研究成果: Article

TY - JOUR

T1 - Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia

AU - Kajiguchi, Masahiro

AU - Kondo, Takahisa

AU - Izawa, Hideo

AU - Kobayashi, Masayoshi

AU - Yamamoto, Koji

AU - Shintani, Satoshi

AU - Numaguchi, Yasushi

AU - Naoe, Tomoki

AU - Takamatsu, Junki

AU - Komori, Kimihiro

AU - Murohara, Toyoaki

PY - 2007/2/5

Y1 - 2007/2/5

N2 - Background: Therapeutic angiogenesis using cell transplantation (TACT) is a treatment strategy for no-option patients with critical limb ischemia (CLI). However, because one-third of treated patients fail to respond, the present study was an exploration of the characteristics of responders and non-responders to this treatment regimen. Methods and Results: Seven CLI patients (3 with Buerger's disease, 4 with arteriosclerosis obliterans undergoing chronic hemodialysis (ASO-HD)) were treated according to the TACT protocol (n=6: bone marrow-mononuclear cells (MNCs); n=1: peripheral blood-MNCs). Subjective symptoms (visual analog scale) and objective findings (extent of ulcer, ankle-brachial pressure index, transcutaneous oxygen pressure, thermography and angiography) were assessed. Numbers of transplanted CD34+, CD133 + and CD34+CD133+ cells were counted. Changes in circulating CD34+ and CD133+ cell numbers were also examined before and after the treatment. All responders (n=3) had Buerger's disease, and ASO-HD patients did not respond well. Among the responders, the numbers of circulating CD34+ and CD133+ cells persistently increased for 1 month after the treatment, but not in non-responders. Conclusions: The TACT regimen improved CLI in patients with Buerger's disease but not in those with ASOHD in this small study. In responders, post procedural circulating CD34+ and CD133+ cells persistently increased for 1 month (ClinicalTrials.gov Identifier: NCT00145262, TACT-NAGOYA).

AB - Background: Therapeutic angiogenesis using cell transplantation (TACT) is a treatment strategy for no-option patients with critical limb ischemia (CLI). However, because one-third of treated patients fail to respond, the present study was an exploration of the characteristics of responders and non-responders to this treatment regimen. Methods and Results: Seven CLI patients (3 with Buerger's disease, 4 with arteriosclerosis obliterans undergoing chronic hemodialysis (ASO-HD)) were treated according to the TACT protocol (n=6: bone marrow-mononuclear cells (MNCs); n=1: peripheral blood-MNCs). Subjective symptoms (visual analog scale) and objective findings (extent of ulcer, ankle-brachial pressure index, transcutaneous oxygen pressure, thermography and angiography) were assessed. Numbers of transplanted CD34+, CD133 + and CD34+CD133+ cells were counted. Changes in circulating CD34+ and CD133+ cell numbers were also examined before and after the treatment. All responders (n=3) had Buerger's disease, and ASO-HD patients did not respond well. Among the responders, the numbers of circulating CD34+ and CD133+ cells persistently increased for 1 month after the treatment, but not in non-responders. Conclusions: The TACT regimen improved CLI in patients with Buerger's disease but not in those with ASOHD in this small study. In responders, post procedural circulating CD34+ and CD133+ cells persistently increased for 1 month (ClinicalTrials.gov Identifier: NCT00145262, TACT-NAGOYA).

UR - http://www.scopus.com/inward/record.url?scp=33846565985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846565985&partnerID=8YFLogxK

U2 - 10.1253/circj.71.196

DO - 10.1253/circj.71.196

M3 - Article

C2 - 17251666

AN - SCOPUS:33846565985

VL - 71

SP - 196

EP - 201

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 2

ER -